Systemic injection of Fms-like tyrosine kinase 3 ligand (Flt3L) has been reported to induce the expansion of immature cDCs at the tumor site [15], whereas immature DCs can’t efficiently prime T cells. The gene discussed is FLT3LG; the disease is neoplasm.